Renoprotective opportunities of Lespedeza capitata in patients with chronic kidney disease and type 2 diabetes mellitus

Main Article Content

S.V. Kushnirenko
D.D. Ivanov
S.A. Rotova
О.V. Kushnirenko


Background. Today, issues of renoprotection have gone beyond the use of antihypertensive therapy alone. Stable glucose-lowering and urate-lowering therapy are integral parts of modern renoprotection, which improve the functional state of the kidneys by increasing the glomerular filtration rate (GFR) and reducing the albumin excretion rate (AER) and the albumin-to-creatinine ratio (ACR). Nevertheless, hypoazotemic therapy aimed at reducing the content of nitrogenous wastes remains the leading component of the treatment of patients with chronic kidney disease (CKD). The aim of the study is the assessment of the renoprotective potential of the drug Libera (Lespedeza capitata) in patients with CKD stages 2–3 on the background of type 2 diabetes mellitus (DM). Materials and methods. The study included 107 patients with type 2 DM, aged 19 to 75 years (female — 41.1 %, male — 58.9 %), CKD stages 2–3, micro- and macroalbuminuria (category A2 and A3). The patients were divided into two groups: group I — traditional stable glucose-lowering and antihypertensive therapy (n = 50) and group II — traditional stable glucose-lowering and antihypertensive therapy in combination with Libera (Lespedeza capitata) (n = 57), which was prescribed 1 capsule t.i.d. regardless of food intake for 3 months. The criteria for the effectiveness of treatment were dynamics of GFR, AER/ACR in daily urine. The observation period for the patients was 3 months. Results. The renoprotective potential of Lespedeza capitata (Libera) was demonstrated after 3 months of treatment in the form of a significant increase in GFR in patients with CKD stage 2 in group II up to 79.0 ± 1.4 ml/min/1.73 m2 in comparison with the initial data (p < 0.01) and the results obtained in group I after 3 months of using only traditional stable glucose-lowering and antihypertensive therapy (p < 0.05). The use of Libera in the complex treatment of patients of the II group with CKD stage 3 against the background of type 2 DM for 3 months had a positive effect on nitrogen and water excretory kidney function, which manifested itself in an improvement in GFR to 56.6 ± 2.1 ml/min/1.73 m2 in comparison with the initial data (p < 0.05) and the results obtained in group I — 50.8 ± 1.9 ml/min/1.73 m2 (p < 0.05). In group I with traditional stable glucose-lowering and antihypertensive therapy, only 3 patients (9.1 %) transferred from category A2 to category A1 (normoalbuminuria) after 3 months and 2 patients (11.8 %) from category A3 to category A2. In group II, the appointment of Lespedeza capitata (Libera) in combination with stable glucose-lowering and antihypertensive therapy facilitated the transfer of 10 patients (27.8 %) from category A2 to A1 and 7 patients (33.3 %) from category A3 to A2 (p < 0.001). Conclusions. Lespedeza capitata (Libera) in combination with traditional stable glucose-lowering and antihypertensive therapy contributes to the preservation and improvement of the filtration function of the kidneys, a decrease in AER/ACR in patients with CKD stage 2–3 (3a і 3b) against the background of type 2 DM and proves renoprotective efficiency and safety.

Article Details

How to Cite
Kushnirenko, S., D. Ivanov, S. Rotova, and Kushnirenko О. “Renoprotective Opportunities of Lespedeza Capitata in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus”. KIDNEYS, vol. 10, no. 3, Sept. 2021, pp. 162-8, doi:10.22141/2307-1257.10.3.2021.239594.
Modern Pharmacotherapy


National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.

Kidney Disease Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150. doi: 10.1038/kisup.2012.64.

ERA-EDTA. Press release: The hidden epidemic: Worldwide, over 850 million people suffer from kidney diseases. Available from: Accessed: Jun 27, 2018.

Fliser D, Wanner C. Precision medicine in diabetic nephropathy and chronic kidney disease. Nephrol Dial Transplant. 2021 Jun 22;36(Supplement_2):10-13. doi: 10.1093/ndt/gfaa380.

Hoerger TJ, Simpson SA, Yarnoff BO, et al. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative. Am J Kidney Dis. 2015 Mar;65(3):403-11. doi: 10.1053/j.ajkd.2014.09.023.

ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021 Jan 1;36(1):87-94. doi: 10.1093/ndt/gfaa314.

Jalal DI, Chertow GM. Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity? Am J Kidney Dis. 2021 Apr;77(4):478-480. doi: 10.1053/j.ajkd.2020.11.007.

Tiku A, Badve SV, Johnson DW. Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet? Am J Kidney Dis. 2018 Dec;72(6):776-778. doi: 10.1053/j.ajkd.2018.07.022.

Kielstein JT, Pontremoli R, Burnier M. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Curr Hypertens Rep. 2020 Oct 31;22(12):102. doi: 10.1007/s11906-020-01116-3.

Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjöström CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016 Jun;18(6):590-7. doi: 10.1111/dom.12654.

Elsafa E, Ali PZ. Protective effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) on microalbuminuria in diabetic patients.Clinical Diabetology 2020;9(3):193-200. doi: 10.5603/DK.2020.0002.

Yarnell EL. Botanical medicines used for kidney disease in the United States. Iran J Kidney Dis. 2012 Nov;6(6):407-18.

Kiliś-Pstrusińska K, Wiela-Hojeńska A. Nephrotoxicity of Herbal Products in Europe-A Review of an Underestimated Problem. Int J Mol Sci. 2021 Apr 16;22(8):4132. doi: 10.3390/ijms22084132.

Lysyuk RM, Darmogray RE. Plants of the genus Lespedeza as promising sources of modern medicines. Fìtoterapìâ. 2015;(2):31-35. (in Ukrainian).

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 11 > >>